A Phase 1b/2 Trial of AMG 479 or AMG 102 in Combination with Platinum-based Chemotherapy as First-Line Treatment for Extensive Stage Small Cell Lung Cancer

Key Inclusion Criteria - Histologically or cytologically confirmed SCLC - Extensive disease, defined by at least one of the following: - No limited disease (ie, no disease confined to the ipsilateral hemithorax, which can be safely encompassed within a tolerable radiation field) - Extrathoracic metastases - Malignant pericardial or pleural effusion - Contralateral hilar adenopathy - Measurable or nonmeasurable disease, as defined by modified RECIST - Eastern Cooperative Oncology Group (ECOG) status 0 or 1 - ≥18 years old - Life expectancy (with therapy) ≥3 months - Adequate hematologic, hepatic, coagulation, renal, and metabolic function - Diabetes, if present, must be controlled, with glycosylated hemoglobin (HbA1C) ≤ 8% and fasting glucose levels ≤160 mg/dL Key Exclusion Criteria - Prior chemotherapy, chemoradiation, or investigational agent for SCLC - Prior radiotherapy to >25% of the bone marrow - Symptomatic or untreated central nervous system metastases (with exceptions) - Currently or previously treated with biologic, immunologic or other therapies for SCLC - Current serious or nonhealing wound or ulcer - History of prior concurrent other malignancy (with exceptions) - Thorombosis or vascular ischemic events within the last 12 months such as DVT, PE, TIA or MI - Any clinically significant medical condition other than cancer (eg, cardiovascular disease or COPD), which could interfere with the safe delivery of study treatment or risk of toxicity